BoironBOIRF 62 EPS without NRI is $1.63 as of Dec. 2025. GuruFocus rates BOIRF with a GF Score™ of 62/100 and a GF Value™ of $39.51 (Fairly Valued). The stock has 4 warning signs investors should review. Among 787 Drug Manufacturers companies, Boiron ranks worse than 79.54% on this metric.
Boiron's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was $0.95.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $1.63.
During the past 12 months, Boiron's average earnings per share (NRI) Growth Rate was -13.40% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -14.00% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -8.70% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was -11.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Boiron's EPS without NRI or its related term are showing as below:
BOIRF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30.2 Med: -1.65 Max: 80.8
Current: -14
During the past 13 years, Boiron's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 80.80% per year. The lowest was -30.20% per year. And the median was -1.65% per year.
BOIRF's 3-Year EPS without NRI Growth Rate is ranked worse than 79.54% of 787
companies
in the Drug Manufacturers industry
Industry Median: 9.7
vs BOIRF: -14.00
Boiron's EPS (Diluted) for the
six
months ended in Dec. 2025 was $1.44.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $2.19.
Boiron's EPS (Basic) for the
six
months ended in Dec. 2025 was $1.44.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $2.19.
Boiron (OTCPK:BOIRF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Boiron EPS without NRI Related Terms
Boiron EPS without NRI Historical Data
* Premium members only.
The historical data trend for Boiron's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOIRF vs ZTS, UTHR, VTRS: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boiron PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Boiron's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Boiron's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boiron (BOIRF) has a EPS without NRI of $1.63 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Boiron and its competitors. According to the industry distribution chart, Boiron ranks #626 out of 787 companies in the Drug Manufacturers industry, placing it in the top 79.5%.
Is Boiron's EPS without NRI too high?
Boiron's current EPS without NRI is $1.63. The Drug Manufacturers industry median EPS without NRI is 9.70. Boiron's value of $1.63 is 83.2% below this industry median. Based on the distribution chart, Boiron ranks #626 out of 787 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Boiron has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Boiron's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Boiron ranks #626 out of 787 companies for EPS without NRI. This places Boiron in the lower half of its industry. The industry median EPS without NRI is 9.70. Boiron's value of $1.63 is 83.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boiron's current EPS without NRI of $1.63 is 83.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Boiron and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boiron's current EPS without NRI is $1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boiron stock overvalued right now?
Based on GuruFocus' analysis, Boiron (BOIRF) is currently considered Fairly Valued. The stock's GF Value™ is $39.51, compared to a current price of $31.90 — trading 19.3% below its estimated fair value. The current EPS without NRI is $1.63 and 83.2% below the Drug Manufacturers industry median of 9.70. Boiron's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Boiron (BOIRF), the current EPS without NRI is $1.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boiron (BOIRF) Overvalued in 2026?
Based on GuruFocus' analysis, Boiron stock appears to be undervalued.
The current stock price of $31.90 is trading 19.3% below its estimated GF Value™ of $39.51.
GuruFocus considers Boiron to be Fairly Valued.
Key valuation signals for BOIRF:
EPS without NRI: $1.63
GF Value™: $39.51 vs. price of $31.90 (19.3% below fair value)
Industry Position: 83.2% below the Drug Manufacturers median (#626 of 787)
No single metric tells the full story. See the BOIRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
62GF Score
Get the complete analysis for BOIRF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOIRF has been successfully added to your 
